TY - JOUR
T1 - Immunohistochemical biomarkers in oral submucous fibrosis
T2 - A scoping review
AU - Kavitha, Loganathan
AU - Ranganathan, Kannan
AU - Shyam, Sivasamy
AU - Fathima, Jaffer Hussain Shazia
AU - Umesh, Wadgave
AU - Warnakulasuriya, Saman
N1 - Funding Information:
This study is supported by Prof. N.S. Azhagarasan, Principal, Ragas Dental College and Hospital, affiliated to The Tamil Nadu Dr. MGR University, Chennai, Tamil Nadu, India. The authors would like to thank Dr. Madan Kumar PD, Dr. Krithika Datta, Dr. T Radhika, Dr. Jayanthi Varun, Dr. Kirthiga Muthusamy, and Dr. Vidya KM for evaluating the content validity of the modified JBI tool.
Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2022/8
Y1 - 2022/8
N2 - Introduction: This scoping review was done to study the immunohistochemical biomarkers involved in the pathogenesis and malignant transformation of oral submucous fibrosis (OSF), in literature published from 2010 to 2021. Method: The protocol was adapted from the Joanna Briggs Institute Reviewer's Manual (2017), and reported according to the PRISMA guidelines for Scoping Reviews. Results: Eighty-six studies included in this review reported 84 immunohistochemical (IHC) biomarkers in OSF: 10 epithelial markers, 28 connective tissue markers, 22 proliferative markers, and 24 other biomarkers that are transcription factors, cancer stem cell markers, cell signaling markers, proteins, and enzymes. The commonly reported IHC biomarkers were alpha-smooth muscle actin (α-SMA) and E-cadherin (seven articles each) followed by vascular endothelial growth factor (VEGF) and CD34 (six articles each), p53, p63, and Ki67 (five articles each). α-SMA, Ki67, CD105, and hTERT were significantly increased in oral squamous cell carcinoma arising in a background of OSF (OSCC-OSF) compared with OSF and normal subjects. Conclusion: The identified surrogate IHC biomarkers reported in OSF in this scoping review require validation with long-term prospective studies to facilitate early diagnosis, for use in risk assessment, and plan appropriate treatment for OSF in clinical practice. Open Science Framework ID: osf.io/epwra.
AB - Introduction: This scoping review was done to study the immunohistochemical biomarkers involved in the pathogenesis and malignant transformation of oral submucous fibrosis (OSF), in literature published from 2010 to 2021. Method: The protocol was adapted from the Joanna Briggs Institute Reviewer's Manual (2017), and reported according to the PRISMA guidelines for Scoping Reviews. Results: Eighty-six studies included in this review reported 84 immunohistochemical (IHC) biomarkers in OSF: 10 epithelial markers, 28 connective tissue markers, 22 proliferative markers, and 24 other biomarkers that are transcription factors, cancer stem cell markers, cell signaling markers, proteins, and enzymes. The commonly reported IHC biomarkers were alpha-smooth muscle actin (α-SMA) and E-cadherin (seven articles each) followed by vascular endothelial growth factor (VEGF) and CD34 (six articles each), p53, p63, and Ki67 (five articles each). α-SMA, Ki67, CD105, and hTERT were significantly increased in oral squamous cell carcinoma arising in a background of OSF (OSCC-OSF) compared with OSF and normal subjects. Conclusion: The identified surrogate IHC biomarkers reported in OSF in this scoping review require validation with long-term prospective studies to facilitate early diagnosis, for use in risk assessment, and plan appropriate treatment for OSF in clinical practice. Open Science Framework ID: osf.io/epwra.
KW - biomarkers
KW - oral squamous cell carcinoma
KW - oral submucous fibrosis
KW - potentially malignant disorders
KW - scoping review
UR - http://www.scopus.com/inward/record.url?scp=85125109395&partnerID=8YFLogxK
U2 - 10.1111/jop.13280
DO - 10.1111/jop.13280
M3 - Review article
C2 - 35102645
AN - SCOPUS:85125109395
SN - 0904-2512
VL - 51
SP - 594
EP - 602
JO - Journal of Oral Pathology and Medicine
JF - Journal of Oral Pathology and Medicine
IS - 7
ER -
